Table 3
Success rates for the clinical and bacteriological responses in the two study arms
| Ciprofloxacin | Imipenem | p value3-150 (95% CI) | |
|---|---|---|---|
| Clinical response: | |||
| Success rate | 29/41 (71%) | 27/34 (79%) | 0.435 (–10.8 to 28.1) |
| Cure | 17/41 (42%) | 22/34 (65%) | |
| Improvement | 12/41 (29%) | 5/34 (14%) | |
| Pseudomonas aeruginosa(n=26) | |||
| Success rate | 10/14 (71%) | 8/12 (67%) | 1.0 (–40.4 to 30.9) |
| Enterobacteriaceae (n=9) | |||
| Success rate | 5/6 (83%) | 2/3 (67%) | 1.0 (–77.8 to 44.4) |
| Bacteriological response: | |||
| Success | 20/41 (49%) | 17/34 (50%) | 1.0 (–21.5 to 23.9) |
| Eradication | 7/41 (17%) | 10/34 (29%) | |
| Presumed eradication | 13/41 (32%) | 7/34 (21%) | |
| Failure | 21/41 (51%) | 17/34 (50%) | |
| Persistence | 2/41 (5%) | 8/34 (24%) | |
| Superinfection | 9/41 (22%) | 5/34 (15%) | |
| Presumed failure | 10/41 (24%) | 4/34 (11%) | |
| Pseudomonas aeruginosa(n=26) | |||
| Success rate | 7/14 (50%) | 3/12 (25%) | 0.247 (–60.9 to 10.9) |
| Enterobacteriaceae (n=9) | |||
| Success rate | 5/6 (83%) | 1/3 (33%) | 0.266 (–111.1 to 11.1) |
-
In addition, subanalysis of patients withPseudomonas aeruginosa and Enterobacteriaceae in baseline culture are shown.
-
↵3-150 p values calculated using χ2 test.
